Published Paper Details:

Choosing the appropriate antifungal has become more difficult because of a rising number of invasive fungal infections and changing resistance patterns. This paper aims to provide insight into how pharmacokinetic properties, characteristics of the fungal organism, and patient-specific factors affect selection of the appropriate antifungal agent. These variables can be narrowed down somewhat according to the susceptibility of particular fungi, the site of infection and pharmacokinetic factors eg, how well a drug reaches within infected tissues or its elimination from the body. Just as they are decisions about the activity of a drug in tumours, there are also factors which relate to the patient as an individual - immune status, renal and hepatic function, total body burdens and possibly other medications. Infections caused by resistant organisms like Candida glabrata and Aspergillus fumigatus call for susceptibility testing and informed treatment decisions. Additionally, the cost, availability, and required duration of treatment must be taken into account, particularly for long-term therapies. Results attributed to resistant Candida glabrata and Aspergillus fumigatus require susceptibility testing and informed therapeutic choices. The price is also being contemplated, in addition to accessibility and the necessary treatment time -- which is particularly relevant for therapies over the long term. Overall, this review emphasizes the importance of a personalized, evidence-based approach to antifungal selection--one that not only improves treatment outcomes but also helps prevent toxicity and drug resistance